U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H44O6
Molecular Weight 428.6035
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIHEPTANOIN

SMILES

CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC

InChI

InChIKey=PJHKBYALYHRYSK-UHFFFAOYSA-N
InChI=1S/C24H44O6/c1-4-7-10-13-16-22(25)28-19-21(30-24(27)18-15-12-9-6-3)20-29-23(26)17-14-11-8-5-2/h21H,4-20H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C24H44O6
Molecular Weight 428.6035
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Triheptanoin (also known as C7 oil) is an investigational medical food or supplement. Triheptanoin is thought to have an anaplerotic role, meaning that it can replenish substances involved in the tricarbolic acid cycle, a pathway used by cells to produce energy, providing an alternative source of energy to the brain. It supplies the body with heptanoate which can either be oxidized to propionyl-CoA directly or is metabolized by the liver to the“C5 ketones”, β-ketopentanoate and/or β-hydroxypentanoate, which are released into the blood. After one month of triheptanoin use, the level of energy production in the brain during visual stimulation had become normal in Huntington’s patients. Triheptanoin was anticonvulsant in two chronic mouse models and increased levels of anaplerotic precursor metabolites in epileptic mouse brains. Despite the unknown mechanism of triheptanoin’s anticonvulsant action, the fact that triheptanoin has been used safely in several animals and for various metabolic diseases in children and adults should expedite the ethical and regulatory approval processes for a clinical trial in medically refractory patients with epilepsy. Triheptanoin is phase II clinical trial for the treatment of glycogen storage disease type V, Huntington's disease, Rett syndrome and amyotrophic lateral sclerosis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
178.9 μM
300 mg/kg single, oral
dose: 300 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIHEPTANOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
259.1 mM
400 mg/kg single, oral
dose: 400 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIHEPTANOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
319.9 μM
300 mg/kg 8 times / 2 days multiple, oral
dose: 300 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRIHEPTANOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
336.5 μM × h
300 mg/kg single, oral
dose: 300 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIHEPTANOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
569.1 μM × h
400 mg/kg single, oral
dose: 400 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIHEPTANOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
789.8 μM × h
300 mg/kg 8 times / 2 days multiple, oral
dose: 300 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRIHEPTANOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Disc. AE: Abdominal pain, Diarrhea...
Other AEs: Upper respiratory tract infection, Gastroenteritis...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (3.4%)
Diarrhea (grade 2, 3.4%)
Other AEs:
Upper respiratory tract infection (grade 1-2, 37.9%)
Gastroenteritis (grade 1-2, 24.1%)
Diarrhea (grade 1-2, 51.7%)
Vomiting (grade 1-2, 37.9%)
Abdominal pain (grade 1-2, 24.1%)
Rhabdomyolysis (grade 1-2, 41.4%)
Pyrexia (grade 1-2, 20.7%)
Headache (grade 1-2, 20.7%)
Nausea (grade 1-2, > 5)
Abdominal distension (grade 1-2, > 5)
Flatulence (grade 1-2, > 5)
Acne (grade 1-2, > 5)
Sources:
35 % caloric input 3 times / day multiple, oral (median)
MTD
Dose: 35 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 35 % caloric input, 3 times / day
Sources:
unhealthy, 3 to 18 years
n = 12
Health Status: unhealthy
Condition: refractory epilepsy
Age Group: 3 to 18 years
Sex: M+F
Population Size: 12
Sources:
30.5 % caloric input 3 times / day multiple, oral (median)
Recommended
Dose: 30.5 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 30.5 % caloric input, 3 times / day
Sources:
unhealthy, 3 to 18 years
n = 12
Health Status: unhealthy
Condition: refractory epilepsy
Age Group: 3 to 18 years
Sex: M+F
Population Size: 12
Sources:
Other AEs: Diarrhea, Constipation...
Other AEs:
Diarrhea (58.3%)
Constipation (16.7%)
Abdominal pain (16.7%)
Vomiting (25%)
Anorexia (8.3%)
Acne (8.3%)
Sources:
1.3 g/kg multiple, oral (total daily dose)
Dose: 1.3 g/kg
Route: oral
Route: multiple
Dose: 1.3 g/kg
Sources:
unhealthy, 4 months to 63 years
n = 79
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 4 months to 63 years
Sex: M+F
Population Size: 79
Sources:
Other AEs: Abdominal pain, Diarrhea...
Other AEs:
Abdominal pain (60%)
Diarrhea (44%)
Vomiting (44%)
Nausea (14%)
Sources:
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Other AEs: Diarrhea, Gastrointestinal upset...
Other AEs:
Diarrhea (31.25%)
Gastrointestinal upset (68.75%)
Emesis (37.5%)
Musculoskeletal pain (68.75%)
Rhabdomyolysis (31.25%)
Fatigue (18.75%)
Headache (31.25%)
Viral infection (93.75%)
Pain localized (25%)
Dermatitis (6.25%)
Hemorrhoids (6.25%)
Depression (6.25%)
Constipation (6.25%)
Nail avulsion (6.25%)
Vertigo (6.25%)
Tooth injury (6.25%)
Sources:
1.25 g/kg/day 4 times / day multiple, oral
Highest studied dose
Dose: 1.25 g/kg/day, 4 times / day
Route: oral
Route: multiple
Dose: 1.25 g/kg/day, 4 times / day
Sources:
healthy
1.5 g/kg/day 1 times / day single, oral
Highest studied dose
Dose: 1.5 g/kg/day, 1 times / day
Route: oral
Route: single
Dose: 1.5 g/kg/day, 1 times / day
Sources:
healthy
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 3.4%
Disc. AE
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Headache grade 1-2, 20.7%
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Pyrexia grade 1-2, 20.7%
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Abdominal pain grade 1-2, 24.1%
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Gastroenteritis grade 1-2, 24.1%
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Upper respiratory tract infection grade 1-2, 37.9%
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Vomiting grade 1-2, 37.9%
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Rhabdomyolysis grade 1-2, 41.4%
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Diarrhea grade 1-2, 51.7%
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Abdominal distension grade 1-2, > 5
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Acne grade 1-2, > 5
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Flatulence grade 1-2, > 5
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Nausea grade 1-2, > 5
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Diarrhea grade 2, 3.4%
Disc. AE
30 % caloric input 4 times / day multiple, oral (mean)
Recommended
Dose: 30 % caloric input, 4 times / day
Route: oral
Route: multiple
Dose: 30 % caloric input, 4 times / day
Sources:
unhealthy, 0.87 to 58.78 years
n = 29
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 0.87 to 58.78 years
Sex: M+F
Population Size: 29
Sources:
Abdominal pain 16.7%
30.5 % caloric input 3 times / day multiple, oral (median)
Recommended
Dose: 30.5 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 30.5 % caloric input, 3 times / day
Sources:
unhealthy, 3 to 18 years
n = 12
Health Status: unhealthy
Condition: refractory epilepsy
Age Group: 3 to 18 years
Sex: M+F
Population Size: 12
Sources:
Constipation 16.7%
30.5 % caloric input 3 times / day multiple, oral (median)
Recommended
Dose: 30.5 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 30.5 % caloric input, 3 times / day
Sources:
unhealthy, 3 to 18 years
n = 12
Health Status: unhealthy
Condition: refractory epilepsy
Age Group: 3 to 18 years
Sex: M+F
Population Size: 12
Sources:
Vomiting 25%
30.5 % caloric input 3 times / day multiple, oral (median)
Recommended
Dose: 30.5 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 30.5 % caloric input, 3 times / day
Sources:
unhealthy, 3 to 18 years
n = 12
Health Status: unhealthy
Condition: refractory epilepsy
Age Group: 3 to 18 years
Sex: M+F
Population Size: 12
Sources:
Diarrhea 58.3%
30.5 % caloric input 3 times / day multiple, oral (median)
Recommended
Dose: 30.5 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 30.5 % caloric input, 3 times / day
Sources:
unhealthy, 3 to 18 years
n = 12
Health Status: unhealthy
Condition: refractory epilepsy
Age Group: 3 to 18 years
Sex: M+F
Population Size: 12
Sources:
Acne 8.3%
30.5 % caloric input 3 times / day multiple, oral (median)
Recommended
Dose: 30.5 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 30.5 % caloric input, 3 times / day
Sources:
unhealthy, 3 to 18 years
n = 12
Health Status: unhealthy
Condition: refractory epilepsy
Age Group: 3 to 18 years
Sex: M+F
Population Size: 12
Sources:
Anorexia 8.3%
30.5 % caloric input 3 times / day multiple, oral (median)
Recommended
Dose: 30.5 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 30.5 % caloric input, 3 times / day
Sources:
unhealthy, 3 to 18 years
n = 12
Health Status: unhealthy
Condition: refractory epilepsy
Age Group: 3 to 18 years
Sex: M+F
Population Size: 12
Sources:
Nausea 14%
1.3 g/kg multiple, oral (total daily dose)
Dose: 1.3 g/kg
Route: oral
Route: multiple
Dose: 1.3 g/kg
Sources:
unhealthy, 4 months to 63 years
n = 79
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 4 months to 63 years
Sex: M+F
Population Size: 79
Sources:
Diarrhea 44%
1.3 g/kg multiple, oral (total daily dose)
Dose: 1.3 g/kg
Route: oral
Route: multiple
Dose: 1.3 g/kg
Sources:
unhealthy, 4 months to 63 years
n = 79
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 4 months to 63 years
Sex: M+F
Population Size: 79
Sources:
Vomiting 44%
1.3 g/kg multiple, oral (total daily dose)
Dose: 1.3 g/kg
Route: oral
Route: multiple
Dose: 1.3 g/kg
Sources:
unhealthy, 4 months to 63 years
n = 79
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 4 months to 63 years
Sex: M+F
Population Size: 79
Sources:
Abdominal pain 60%
1.3 g/kg multiple, oral (total daily dose)
Dose: 1.3 g/kg
Route: oral
Route: multiple
Dose: 1.3 g/kg
Sources:
unhealthy, 4 months to 63 years
n = 79
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 4 months to 63 years
Sex: M+F
Population Size: 79
Sources:
Fatigue 18.75%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Pain localized 25%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Diarrhea 31.25%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Headache 31.25%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Rhabdomyolysis 31.25%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Emesis 37.5%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Constipation 6.25%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Depression 6.25%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Dermatitis 6.25%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Hemorrhoids 6.25%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Nail avulsion 6.25%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Tooth injury 6.25%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Vertigo 6.25%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Gastrointestinal upset 68.75%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Musculoskeletal pain 68.75%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Viral infection 93.75%
20 % caloric input 3 times / day multiple, oral
Dose: 20 % caloric input, 3 times / day
Route: oral
Route: multiple
Dose: 20 % caloric input, 3 times / day
Sources:
unhealthy, 7 to 64 years
n = 16
Health Status: unhealthy
Condition: long-chain fatty acid oxidation disorders
Age Group: 7 to 64 years
Sex: M+F
Population Size: 16
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy.
2005 Apr
Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential.
2006 Apr-Jun
Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats.
2006 Oct
Use of glyceroltriheptanoate as marker for processed animal by-products: development and validation of an analytical method.
2009 Apr
Inborn errors of energy metabolism associated with myopathies.
2010
[Hepatic fatty acid profile of rats with AIN-93 diet-induced steatosis attenuated by the partial substitution of soybean oil by diheptanoin and triheptanoin].
2010 Aug
Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models.
2010 Dec
Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. II. Effects on lipolysis, glucose production, and liver acyl-CoA profile.
2010 Feb
Current issues regarding treatment of mitochondrial fatty acid oxidation disorders.
2010 Oct
Adult Polyglucosan Body Disease (APBD): Anaplerotic diet therapy (Triheptanoin) and demonstration of defective methylation pathways.
2010 Oct-Nov
Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's disease.
2010 Sep
Substance Class Chemical
Created
by admin
on Sat Jun 26 05:49:31 UTC 2021
Edited
by admin
on Sat Jun 26 05:49:31 UTC 2021
Record UNII
2P6O7CFW5K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRIHEPTANOIN
INCI  
INN   USAN   INCI  
Official Name English
UX007
Code English
GLYCERYL TRIHEPTANOATE
Systematic Name English
PROPANE-1,2,3-TRIYL TRIHEPTANOATE
Systematic Name English
HEPTANOIN, TRI-
Common Name English
LANOL 37 T
Brand Name English
RADIAMULS 2375
Brand Name English
DUB THG
Brand Name English
TRIHEPTANOIN [WHO-DD]
Common Name English
TRIHEPTANOIC GLYCERIDE
Common Name English
TRIHEPTANOIN [INN]
Common Name English
DOJOLVI
Brand Name English
HEPTANOIC ACID, 1,2,3-PROPANETRIYL ESTER
Common Name English
TRIHEPTANOIN [USAN]
Common Name English
HEPTANOIC ACID, 1,1',1''-(1,2,3-PROPANETRIYL) ESTER
Systematic Name English
TRIENANTHOIN
Common Name English
GLYCEROL TRIHEPTANOATE
Systematic Name English
DERMOFEEL TC 7
Brand Name English
TRIOENANTHOIN
Common Name English
TRIHEPTANOIN [INCI]
Common Name English
UX-007
Code English
DERMOFEEL TC-7
Brand Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 426414
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
FDA ORPHAN DRUG 474015
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
FDA ORPHAN DRUG 220406
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
EU-Orphan Drug EU/3/12/1081
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
FDA ORPHAN DRUG 220306
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
210-647-2
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
PRIMARY
PUBCHEM
69286
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
PRIMARY
NCI_THESAURUS
C166587
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
PRIMARY
MESH
C531010
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
PRIMARY
DRUG BANK
DB11677
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
PRIMARY
WIKIPEDIA
TRIHEPTANOIN
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
PRIMARY
CAS
620-67-7
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
PRIMARY
RXCUI
1313234
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
PRIMARY RxNorm
FDA UNII
2P6O7CFW5K
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
PRIMARY
INN
10893
Created by admin on Sat Jun 26 05:49:31 UTC 2021 , Edited by admin on Sat Jun 26 05:49:31 UTC 2021
PRIMARY
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY